生物製药第三方物流市场规模、份额、趋势分析报告：依供应链、按服务类型、按地区、细分市场预测，2025-2030年

生物製药第三方物流市场成长与趋势

Grand View Research, Inc.的最新报告显示，到2030年，全球生物製药第三方物流市场规模预计将达到2,090亿美元。预计2025年至2030年该市场将以6.58%的复合年增长率成长。对跨地区运输生技药品的温控物流服务的需求不断增加，以及生物製药公司扩大分销网络以提高销售队伍，这是推动市场成长的因素。新兴国家越来越多地采用自动化储存和搜寻系统是一个持续的趋势，也是製药物流公司的主要驱动力。

此外，从小分子药物转型为生技药品）的趋势预计将推动市场。由于这些小分子药物是温度敏感产品，对温控运输和储存的需求不断增加，促进了市场成长。技术进步是推动市场成长的关键因素之一。行动云端解决方案、仓库机器人和资料探勘等技术已经改变了整个 3PL 领域。借助这些先进技术，3PL 公司能够在运输过程中保持产品所需的温度。

这降低了产品复杂性和人为错误。大多数生物药品对温度非常敏感，必须在要求的温度下储存。此类产品需要追踪设备进行监控直至交付。例如，2023年5月，Tridentify推出了具有创新能力的即时低温运输监控系统，能够持续追踪低温运输中运输的产品的稳定性和剩余保质期。该系统有望透过提供有关药物稳定性和剩余保质期的即时详细信息，彻底改变公司监控业务和管理稳定性预算的方式。

此外，出于环境考量和成本考虑，商业产品的运输方式逐渐从空运转向海运，道路运输从卡车转向多式联运（铁路和卡车）。这些製药公司主要使用多式联运来减少碳排放。从目前的趋势来看，药品製造商正在转向海运，以降低成本和风险因素。对于低温运输产品，企业还是更青睐航空运输。然而，一些大型製药公司计划透过海运运输其70%的产品，其中包括低温运输产品。

生物製药第三方物流市场报告亮点

• 2024年，由于不需要温度控制的药品数量庞大，非低温运输物流领域占销售额的最大份额为79.7%。
• 由于对细胞疗法、疫苗和检测套组等生技药品的需求，低温运输物流领域预计在预测期内复合年增长率为 9.40%。
• 仓储领域占比最大，2024年将达43.3%。由于公司内部能力不足，2024年运输部门也占了很大的收益占有率。
• 由于生物製药进出口增加，2024年北美地区收益占有率最大，超过42.53%。
• 由于人口老化以及药品销售从品牌製造商转向非专利製造商的转变，预计亚太地区在预测期内的复合年增长率将达到 7.4%，是最快的。
• 主要企业正在采取多项策略措施来提高其在市场上的影响力。例如，2021年2月，德迅与中国最大的非国有药品分销公司九州通建立伙伴关係，以加强其在中国的医疗医药物流足迹。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章生物製药第三方物流市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关/补充市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
  • 市场机会分析
  • 市场问题分析
• 市场分析工具
  • 波特五力分析
  • PESTEL分析
  • COVID-19 影响分析

第四章生物製药第三方物流市场：供应链、估算与趋势分析

• 细分仪表板
• 全球生物医药第三方物流市场、供应链波动分析
• 2018-2030年全球生物製药第三方物流规模及趋势分析（依供应链）
• 低温运输物流
• 非低温运输物流

第五章生物製药第三方物流市场：服务类型、估算与趋势分析

• 细分仪表板
• 全球生物医药第三方物流市场、服务类型变化分析
• 2018-2030年全球生物製药第三方物流规模及趋势分析（依服务类型）
• 运输
  • 航空货运
  • 海运
  • 陆上
• 仓库/仓储
• 其他的

第六章生物製药第三方物流市场：区域、估计与趋势分析

• 2024 年及 2030 年按地区分類的市场占有率分析
• 区域市场仪表板
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 丹麦
  • 瑞典
  • 挪威
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 泰国
• 拉丁美洲
  • 巴西
  • 阿根廷
• 中东/非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第七章 竞争格局

• 公司分类
• 2024 年企业市场分析
• 公司简介
  • DHL International GmbH
  • SF Express
  • FedEx
  • United Parcel Service of America, Inc.
  • Cencora, Inc
  • DB Schenker
  • Kuehne and Nagel
  • Kerry Logistics Network Limited
  • Agility Public Warehousing Company KSCP

Biopharmaceutical Third-party Logistics Market Growth & Trends:

The global biopharmaceutical third-party logistics market size is anticipated to reach USD 209.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.58% from 2025 to 2030. Increasing demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the market growth. The rising adoption of automated storage and retrieval systems in emerging countries is an ongoing trend among pharmaceutical logistics companies that has gained significant traction.

Furthermore, the trend of shifting from small-molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature-sensitive products, demand for temperature-controlled transportation and storage increases and thus, is responsible for the market growth. Technological advancements are among the main factors drivingmarket growth. Technologies, such as mobile cloud solutions, warehouse robotics, and data mining, have changed the overall 3PL space. With the help of these advanced technologies, 3PL companies can maintain the required temperatures for products during transportation.

This will help in reducing complexities in products and human errors. Most biopharmaceutical products are very temperature-sensitive and hence should be stored at the required temperatures. These products require a tracking device for monitoring until delivery. For instance, in May 2023, Tridentify launched a real-time cold chain monitoring system with an innovative feature for continuously tracking the stability and remaining shelf life of products transported in the cold chain. It offers a thorough view of the stability and remaining shelf-life of pharmaceutical products in real-time, which will revolutionize the way companies monitor their operations and manage their stability budgets.

In addition, environmental concerns and costs have caused a slight shift in the means of transport used for commercial products, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck) transport. Intermodal transport is majorly used by these pharmaceutical companies to reduce their carbon footprint. The ongoing trend shows that pharmaceutical manufacturers have shifted to sea freight to reduce the cost and risk factors. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Biopharmaceutical Third-party Logistics Market Report Highlights:

• In 2024, the non-cold chain logistics segment held the largest share of 79.7% in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control.
• The cold chain logistics segment is expected to register a CAGR of 9.40% over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits.
• The warehousing and storage segment held the largest share of 43.3% in 2024. The transportation segment also held a significant revenue share in 2024 due to the lack of internal capabilities of companies.
• North America held the largest revenue share of over 42.53% in 2024 owing to the rise in imports and exports for biopharmaceutical in the country.
• Asia Pacific is expected to register the fastest CAGR of 7.4% over the forecast period owing to the adoption of medicines from the aging population and the shift of drug sales from brand manufacturers to generic.
• The key players are undertaking several strategic initiatives to strengthen their market presence. For instance, in February 2021, Kuehne+Nagel entered into a partnership with China's largest non-state-owned pharma distribution company, Jointown, to enhance its footprint in healthcare & pharmaceutical logistics in China.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Third-Party Logistics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in logistics
    • 3.2.1.2. Growing applications of reverse logistics in biopharmaceutical industry
    • 3.2.1.3. Rising demand for cold chain logistics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Compliance issues while outsourcing
    • 3.2.2.2. Stringent regulatory framework
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biopharmaceutical Third-Party Logistics Market; Supply Chain Movement Analysis
• 4.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Supply Chain, 2018 to 2030 (USD Million)
• 4.4. Cold Chain Logistics
  • 4.4.1. Cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Non-cold Chain Logistics
  • 4.5.1. Non-cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Biopharmaceutical Third-Party Logistics Market: Service Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biopharmaceutical Third-Party Logistics Market; Service Type Movement Analysis
• 5.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
• 5.4. Transportation
  • 5.4.1. Transportation market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Air Freight
    • 5.4.2.1. Air freight market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Sea Freight
    • 5.4.3.1. Sea freight market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Overland
    • 5.4.4.1. Overland market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Warehousing and Storage
  • 5.5.1. Warehousing and storage market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other Services
  • 5.6.1. Other services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Biopharmaceutical Third-Party Logistics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. North America
  • 6.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Competitive scenario
    • 6.3.2.3. Regulatory framework
    • 6.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Competitive scenario
    • 6.3.3.3. Regulatory framework
    • 6.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Competitive scenario
    • 6.3.4.3. Regulatory framework
    • 6.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Competitive scenario
    • 6.4.5.3. Regulatory framework
    • 6.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Competitive scenario
    • 6.4.6.3. Regulatory framework
    • 6.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Competitive scenario
    • 6.4.7.3. Regulatory framework
    • 6.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Competitive scenario
    • 6.4.8.3. Regulatory framework
    • 6.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Competitive scenario
    • 6.4.9.3. Regulatory framework
    • 6.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Competitive scenario
    • 6.5.7.3. Regulatory framework
    • 6.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Competitive scenario
    • 6.6.3.3. Regulatory framework
    • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Competitive scenario
    • 6.7.5.3. Regulatory framework
    • 6.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Company Market Position Analysis, 2024
• 7.3. Company Profiles
  • 7.3.1. DHL International GmbH
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Service benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. SF Express
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Service benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. FedEx
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Service benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. United Parcel Service of America, Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Service benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Cencora, Inc
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Service benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. DB Schenker
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Service benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Kuehne and Nagel
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Service benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Kerry Logistics Network Limited
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Service benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Agility Public Warehousing Company K.S.C.P.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Service benchmarking
    • 7.3.9.4. Strategic initiatives

List of Tables

• Table 1 List of Tables
• Table 2 List of Secondary Sources
• Table 3 List of Abbreviations
• Table 4 Global Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 5 Global Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 6 Global Biopharmaceutical Third-Party Logistics, by Region, 2018 - 2030 (USD Million)
• Table 7 North America Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
• Table 8 North America Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 9 North America Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 10 U.S. Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 11 U.S. Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 12 Canada Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 13 Canada Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 14 Mexico Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 15 Mexico Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 16 Europe Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
• Table 17 Europe Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 18 Europe Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 19 UK Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 20 UK Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 21 Germany Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 22 Germany Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 23 France Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 24 France Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 25 Italy Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 26 Italy Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 27 Spain Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 28 Spain Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 29 Denmark Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 30 Denmark Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 31 Sweden Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 32 Sweden Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 33 Norway Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 34 Norway Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 37 Asia Pacific Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 38 Japan Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 39 Japan Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 40 China Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 41 China Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 42 India Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 43 India Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 44 Thailand Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 45 Thailand Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 46 South Korea Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 47 South Korea Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 48 Australia Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 49 Australia Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 50 Latin America Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
• Table 51 Latin America Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 52 Latin America Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 53 Brazil Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 54 Brazil Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 55 Argentina Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 56 Argentina Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 59 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 60 South Africa Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 61 South Africa Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 63 Saudi Arabia Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 64 UAE Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 65 UAE Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
• Table 66 Kuwait Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
• Table 67 Kuwait Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Biopharmaceutical Third-Party Logistics Market revenue, 2018 - 2030 (USD Million)
• Fig. 10 Biopharmaceutical Third-Party Logistics Market snapshot
• Fig. 11 Biopharmaceutical Third-Party Logistics Market driver impact
• Fig. 12 Biopharmaceutical Third-Party Logistics Market restraint impact
• Fig. 13 Biopharmaceutical Third-Party Logistics Market: Supply Chain takeaways (USD Million)
• Fig. 14 Biopharmaceutical Third-Party Logistics Market: Supply Chain movement analysis
• Fig. 15 Cold Chain Logistics market, 2018 - 2030 (USD Million)
• Fig. 16 Non-cold Chain Logistics market, 2018 - 2030 (USD Million)
• Fig. 17 Biopharmaceutical Third-Party Logistics Market: Service Type takeaways (USD Million)
• Fig. 18 Biopharmaceutical Third-Party Logistics Market: Service Type movement analysis
• Fig. 19 Transportation market, 2018 - 2030 (USD Million)
• Fig. 20 Air Freight market, 2018 - 2030 (USD Million)
• Fig. 21 Sea Freight market, 2018 - 2030 (USD Million)
• Fig. 22 Overland market, 2018 - 2030 (USD Million)
• Fig. 23 Warehousing and Storage market, 2018 - 2030 (USD Million)
• Fig. 24 Other Services market, 2018 - 2030 (USD Million)
• Fig. 25 Regional marketplace: Key takeaways
• Fig. 26 Regional outlook, 2024 & 2030
• Fig. 27 North America Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 28 U.S. Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 29 Canada Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 30 Mexico Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 31 Europe Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 32 UK Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 33 Germany Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 34 France Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 35 Italy Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 36 Spain companion animal Health market, 2018 - 2030 (USD Million)
• Fig. 37 Sweden Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 38 Denmark Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 39 Norway Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 40 Asia Pacific Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 41 Japan Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 42 China Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 43 India Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 44 Thailand Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 45 South Korea Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 46 Australia Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 47 Latin America Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 48 Brazil Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 49 Argentina Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 50 Middle East & Africa Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 51 South Africa Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 52 Saudi Arabia Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 53 UAE Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 54 Kuwait Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
• Fig. 55 Market participant categorization